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Methods.The actionsof CNPwerestudiedin instrumented
dogsandin organchamberingsin thepresenceandabsenceof











aminoacidvasoactivepeptide(l). CNP representsthe third
memberof a familyofstructurallyhomologousbutgenetically





ation(6).AlthoughCNPsharesmanyof the actionsof ANP,














CNP-20,103.3& 13.6*[*P < 0.05vs. baselinevalue])and
reducedcoronaryvascularresistance(baseline,1.6 & 0.3 mm
Hg/mlper rein;CNP-5,1.4A 0.3*;CNP-20,1.2& 0.3*).Intra-
coronaryinjectionsincreasedcoronarybloodflow(A baseline
coronaryflow,30 f 9* ml/min[*P< 0.05]).HS-142-1signifi-
cantlyattenuatedthese increases(A coronaryflow,30 & 9*
ml/min[CNP]to14A6t [CNP+ HS-142-1][~pc 0.05CNPvs.











does not act as a mediator for natriuresis.The lack of
CNP-mediatednatriuresisoccursin part becauseCNP and
ANP bind to differentreceptors(7). CNPis the ligandfor a
particulateguanylateeyclase-linkedreceptor knownas the
NPR-B receptor (2,7). The NPR-B receptor is genetically
distinctfromthe receptor(NPR-A)for ANP and BNP.The
NPR-Breceptoris preferentiallyexpressedin cardiactissue
and vascularsmoothmuscle,whereasthe NPR-Areceptoris
highlyexpressedin the kidney(8).Recently,Stingoet al. (9)
andSugaet al. (10)reportedthat endothelialcellssynthesize,
store and releaseCNP,demonstratingthat CNP is of endo-
thelial cell origin (11). In addition,Wei et al. (12) have




hyperpolarizationfactorand prostacyclinas potent coronary
vasodilators.The localizationof the CNPreceptorto cardiac
tissueand vascularsmoothmuscleand the observationthat
CNPis of endothelialcelloriginsuggesta potentialrole for




















The current”investigationwas undertakenwith several
objectives.We soughtto determine1) whetherCNP relaxes
preconstructedepicardialcaninecoronaryarteries,2) whether








and in anesthetizeddogsfor the in vivoprotocols.
Organ chamber protocol.Rings of epicardialcoronary





2.5 CaC12,1.2 MgS04, 1.2 KH2P04,25.0 NaHC03, 0.026
CaNa2EDTAand 11.1dextrosecontrolsolution)at 37°C.In
halfofthevesselrings,theendotheliumwasremovedbygently
rubbingthe intimalsurfacewith a cotton swabwettedwith
controlsolution.Eachringwasstretchedto the optimalpoint
on its length-tensioncurve as determinedby the maximal
tensiondevelopedto potassiumchloride(20millimol/liter)at
eachlevelof stretch.The functionalpresenceof endothelium
was determinedat the beginningof the experimentby a
relaxationresponseto acetylcholine(10–6molfliter)duringa
contractionto PGF2a(2 X 10-6molfliter)at optimallength.
To studyresponsesto CNP, the ringswere contractedwith
PGF2a(2 x 10-6mol/liter).A dose-responsecurveto cumu-
lativeconcentrationsofCNP(10-10molfliterto 3 X 10-6mol/
liter) was obtained,and finalresultswere obtainedutilizing
10-7molfliterCNP.For fivestudiesinvolvingthe particulate
guanylatesystem,a novelinhibitor,HS-142-1,wasutilizedat a




(Sigma).HS-142-1was providedby two of the investigators





dayof study,the dogswerefastedovernightbut allowedfree
accessto tap water. They were anesthetizedwith sodium
pentobarbital(30mg/kgbodyweightintravenously)and ven-
tilatedwithroomair and supplementaloxygenat 4 liters/rein
(HarvardRespiratory).Afterinductionofanesthesia,eachdog
underwenta leftthoracotomyto exposetheanteriorwallofthe
leftventricle.One centimeterof the proximalleft circumflex




Inc.) for measurementof coronaryblood flow.At least 30
minutesoftimewasallowedto elapseto ensurestabilityof the
preparationand consistencyof baselinecoronaryflow.All






Proximalto the flowmeter, a smallneedlewas carefully
positionedin the artery to allowinfusionof CNP or saline
solutionto the coronarycirculation,Eachdogalsounderwent
placementof polyethylenecatheters into the left femoral
arteryandvein.ThefemoraIarterycatheterwasconnectedto
a fluid-filledStathamtransducerfor measurementof arterial
pressure.A leftventricular(LV)catheterwasadvancedfrom
the right femoral artery into the LV and connectedto a
Stathamfluid-filledtransducerto measureLV pressureand
allowcalculationof its firstderivative,dP/dt.A 6F pigtailLV
catheterwasusedin the firstseriesof experimentsand a high
fidelityMillarpressuretransducerLV catheter in all subse-
quentexperiments.A balloon-tipped,flow-directedpulmonary
arterycatheterwasadvancedthroughthe left externaljugular
veinfor measurementof rightheart pressuresand for calcu-
lationofcardiacoutputbyusingthe thermodilutiontechnique
(AmericanEdwardsLaboratories,Inc.). Cardiacoutputwas
recordedas the averageof four measurements.Continuous
recordingsof coronaryblood flow,mean arterial pressure,
right atrial and pulmonaryartery pressure and LV end-
diastolicpressurewereperformedona model2200Gouldstrip
recorder.
After surgicalinstrumentation,each dog underwentan
equilibrationperiod to establishand ensure stabilityof the
preparation.Each animal received a systemicintravenous
infusionof normalsalinesolutionat 2 ml/minand an intra-
coronaryinfusionofnormalsalinesolutionat 1ml/minduring
the equilibrationperiod. The intravenoussaline infusion






by an intracoronaryinfusion.The equilibrationperiod was
followedby a baselineperiod for measurementof cardiac
hemodynamicdata, mean arterial pressure,coronaryblood
flowand dP/dtand by two successive45-minperiodsduring







pletionof the 5-rig/kgper min infusion.The infusiondoses
were basedon data from previousstudies(3,4)that demon-
strated potent in vivoresponsesto CNP. No dog had any
cardiacrhythmabnormalitiesduringthe intracoronaryCNP
infusion.
HS-142-1protocol.In a second series of experiments,
we tested the actionsof intracoronaryHS-142-1on CNP-
mediatedcoronaryvasodilation.Becauseof the need for a
continuousintracoronaryHS-142-1infusion,we utilizedan
intracoronarybolus(100rig/kg)of CNPrather than an intra-
coronaryinfusionasinthefirstseriesofexperiments.Thedose
of CNPwas basedon data frompreviousstudieswith CNP





use of the openthoracotamymethoddescribedearlier.Basal
corona~ bloodflowdid not significantlychangein the pres-
enceofintracoronaryHS-142-1(33t 4ml/minbeforevs.40t
2 ml/minwithHS-142-1,p = NS).In additionto intracoronary
CNP,weadministeredan intracoronarybolusof acetylcholine
(1 n@g) to serve as a control agent and to excludea
nonspecificinhibitoryactionbyHS-142-1oncoronaryvasomo-
tor function.All hemodynamicmeasurementswere made as
describedbefore.At least 15minelapsedbetweenperiodsto
allowcompletewashoutof the tested peptideor substance.
Thisintervalwasconsideredadequatebecausethe half-lifeof
CNPandHS-142-1isgenerallybelievedto be =2 mininvivo.
L-NMMAprotocol,In a thirdseriesof experiments,intra-
coronaryNG-monomethyl-L-arginine(L-NMMA)wasinfused








coronaryinfusionof L-arginine(1 mglkgper rein)to reverse
the effectsof L-NMMAon the coronarynitricoxidesystem.
Again,>15 minwasallowedto elapsebetweenperiods.
Immunohistochemicalprotocol.Epicardialcoronaryarter-
ies were obtainedfrom sevendogs.Theywere preparedas














trationsof CNPin a vesselwithandwithoutendothelium.M =
. WO= washout.mol/liter;PGF2.,P~,= postaglandinFz..lPh~,
endothelialdenudation.Alltissuespecimensweretlxedin 10’%
bufferedformalin,embeddedin paraffin,sectionedat 6 ~m
intervalsand stainedfor CNP, as previouslydescribed,with
CNPantibodyobtainedfromPeninsulaLaboratories.Normal
rabbit serum was used for control. There was no cross-
reactivitybetweenthe CNPantibodyandANPandBNP.The
slideswere independentlyreviewedand interpretedby two
investigators.Slidemagnificationis at X1,000.
Statisticalanalysis.Data are expressedas meanvalue f
SEM.Data were analyzedand consideredsignificantwith a
two-tailedp value < 0.05.Paired t testingwas utilizedto
compareindividualinterventionperiodswith controlvalues
and repeatedmeasuresanalysisof variance;the Fisherleast
significancetestwasutilizedformultiplecomparisonsin the in
vivo studies.Paired and unpaired t testing, corrected for









2. CNP mediatedpotent relaxationin the isolatedepicardial
coronaryarteriesin the presence(45.9* 7Y0,p < 0.05)and
absence(72.0f 770,p < 0.05)of the intactendothelium.In
addition,thevasorelaxingactionofCNPwasindependentofand
actuallyenhanced(p < 0.05)by removalof the endothelium.
Table 1 reportsthe dose-responseand medianeffectivedose
ED50dataforCNP-mediatedrelaxation.CNPmediatedminimal
vasorekxationat lowconcentrations(–) logmol/literof –10and












(1 x 10-7molfliter)in the presenceand absenceof an intact
endothelium.*p<0.05versusbaseline.tp <0.05versusvesselswith
an intactendothelium.
In vivoresponses.Figure3 and Table2 report the hemo-
dynamicdatafromthe in vivoCNPadministration.Intracoro-
naryCNPincreasedcoronarybloodflowandreducedcoronary
vascularresistanceat both infusiondoses.CNP infusiondid
not alter cardiac output, atrial fillingpressures,coronary
perfusionpressureor systemicvascularresistance,but it was
associatedwith a smallbut significantincrease in cardiac
contractility(as assessedby an increasein dP/dt)at the low
dose.CNPappearedto increasecontractilityat the highdose,
but the p valuewas slightlynonsignificant(p < 0.08)when
correctedfor multiplecomparisons.Most likely,this finding
representsa typeII statisticalerror ratherthana lackofeffect
byCNP.CNPwasmeasuredin arterialplasmaand in plasma
obtainedfromthe coronarysinusof eachdogbeforeinfusion
of peptide and at the maximalinfusiondose. Preinfusion
valuesof CNPwerecomparablein the coronarysinus(6.9 t
0.8 ng/dl)and descendingaorta (8.8 f 1.9 ng/dl,p = NS),
demonstratingno cardiacstepupof CNP as existsfor ANP.

























tem. Figure4 illustratesthe actionof intracoronaryHS-142-1
on CNP and acetylcholine-mediatedcoronaryvasodilation.
CNPmediatedpotentincreasesin coronarybloodflow,which







in cardiachemodynamicvariables(Table3) or basalcoronary
blood flow (33 f 4 ml/minbaselinevs. 40 t 2 ml/min
HS-142-1,p = NS).The lackof attenuationof acetylcholine-
mediatedcoronaryvasodilationbyHS-142-1andthe lackofan
effectof HS-142-1on basalcoronaryflowestablishthe lackof
a generalizedtoxiceffectof HS-142-1on coronarytone and
coronaryffowreserve.





10 9 8 [(-)@
Endothelium (%relaxation) (%relaxation) (%relaxation) (%rel~ation) mollliter]
Present(n = 5) o ~ 0% o? o% 18? 8% 46~ 7%* 7.220.3
Absent(n = 5) o * ()% 08 ~ 0,1% 27~ 7% 72~ 7%* 7.4? 0.2









CO(liters/rein) 1.9t 0.2 2.0&0.2 1.9? 0.1
PCWP(mmHg) 4~1 421 5~1
CPP(mmHg) 95* 9 100~ 12 105? 10
SVR(mmHgilitersperrein) 52~ 6 51~ 6 56~ 4
dP/dt(AmmHg/s) 2,645? 129 3,120* 126” 2,851t 163
*p<0.05versusbaseline,CNP-5andCNP-20= intracoronaryinfusionof5
and20mgkgperrein,respectively,ofC-typenatriureticpeptide;CO= cardiac
output;CPP= coronaryperfusionpressure;dP/dt= maximalrate ofriseofleft
ventricularsystolicpressure(contractility);PCWP= pulmonarycapillarywedge
pressure;SVR= systemicvascularesistance.




cardialcoronaryarteriesin the presence(56 t 7’%vs. 18 t
6%*)and absence(61 t 6% vs.25 ~ 7%*)of endothelium
(*p z 0.05CNPalonevs.CNP + HS-142-1).
Modulationof corouary nitric oxide synthase system.
Table 4 summarizesthe modulatingeffectsof the coronary
nitricoxidesynthasesystemon CNP-mediatedcoronaryvaso-
dilation.Infusionof intracoronaryL-NMMAdid not affect
CNP-mediatedcoronaryvasodilation.In addition,intracoro-
nary L-NMMAdid not alter basal coronaryflow,coronary
diameter,cardiacoutputor systemicvascularesistance.There





the coronarycirculation.CNP is localizedin the smooth
muscleandendothelium(panelsA andB) ofa controldog.In
a representativeartery taken from a dogwith intracoronary
infusionof CNP,thereismoreintensestainingof CNPin the




The coronarycirculationis a complexcirculatoryunit
regulatedbyseveralendogenousvasodilatorandvasoconstric-
tive mechanisms(16).Recent studies(16)have emphasized
the importanceof endothelialcell-derivedsubstanceslike
nitric oxide, endothelialcell hyperpolarizationfactor and
prostacyclinas potent coronaryvasodilators.The localization
of the CNP receptorto cardiactissueand vascularsmooth
musclesuggestsa potentialrole for CNPas a vasodilatorfor
the coronarycirculation.Our hypothesisthat CNP would
functionas a coronaryvasodilatorwasconfirmedby the data




“p<o.05 vs pre-CNP value,

















coronaryvasodilationof CNPto the secondmessengercyclic
guanosinemonophosphate(cGMP).
Intracorona~ actions. Intracoronaryinfusionand bolus
injectionsof CNP were associatedwith increasedcoronary
blood flow and reduced coronaryvascularresistance.The
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Table3. CardiacHemodynamicResponsestoHS-142-1
Baseline HS-142-1 Recovery
CO(liters/rein) 2.7* 0.3 2.6~ 0.2 2.5? 0.1
PCWP(mmHg) 5*1 5~2 6~2
CPP(mmHg) 100? 9 100? 7 101t 9
SVR(mmHg/litersper rein) fjg~ 10 (jg* 1(J 70* 10
CBF(ml/min) 33* 4 37~ 6 43* 5
ACVR(AmmHg/mlper rein) –1.4t 0.3” –05 ~ O.lt –0.9i O.1*
*p <0.05 versusvaluebeforeCNPbolus.~p <0.05 versusbaselinevalue.CBF= basalcoronarybloodflow;
ACVR= changein coronaryvascularesistance;otherabbreviationsas inTable2.
from the currentobservationswith HS-142-1.HS-142-1is a
knowninhibitorof the particulateguanylatecyclasesubunit,
whichis internallylinkedwiththe NPR-Aand NPR-Brecep-
tors (13).
In the presentstudy,intracoronaryadministrationof HS-
142-1selectivelyattenuatedCNP-mediatedcoronaryvasodila-
tionwithoutalteringacetylcholine-mediatedcoronaryvasodi-
lation. This observation suggests that a mechanism of
CNP-mediatedcoronaryvasodilationis indeed through a
cGMP-linkedresponsesecondaryto activationof particulate
guanylatecyclasebywayoftheNPR-Breceptor,andit extends









intactin the presenceof HS-142-1.The currentfindingsthus
demonstratethat CNPmediatesitsvasodilationthroughacti-
vationoftheparticulateguanylatecyclasesystem.Inhibitionof
activationof the particulatesystemdidnot alter the abilityof
nitricoxideto mediatecoronaryvasodilationthroughactiva-
tionof the solubleguanylatecyclasesystem.Thus,the current
investigationsupportsa roleforat leasttwoseparatepathways
for cGMP-mediatedcorona~ vasodilationthroughactivation
of the solubleand particulateguanylatecyclase-dependent
systems.
CNP appearsto mediatecoronaryvasodilationpredomi-
nantlyat the levelof the coronaryresistancevessels,as was




actionin the nonepicardialresistancevessels,and it is consis-
tent with the long-standingrecognitionthat the coronary
resistancevesselsaccountfor the majorautoregulatorycapac-
itywithinthe coronarycirculation.The doseof CNPused to
achievethiseffectwasclearlypharmacologic,as wasdemon-
strated by our measuringof plasmalevelsbefore and after
infusionof CNP.Wewereunableto clearlyascertainthe role
of endogenousCNP in mediatingcoronaryvasodilationbe-
causeof the lack of specificityof HS-142-1in blockingthe
NPR-Breceptoralone.HS-142-1isa nonspecificantagonisto
boththeNPR-AandNPR-Breceptors.To fullytestthe roleof
endogenousCNPon basalcoronaryflow,one wouldneed a
specificantagonistto the NPR-B receptor to excludeany
countermodulatoryrolesof ANP and BNPon basalcoronary
flowthroughactivationof the NPR-Areceptor.Additionally,
the inconsistencieswithinbasalcoronaryflowvaluesreflected
in Tables3 and 4 when comparedwith valuesin Figure3
simplyreflectthe variabilityof differentanimalpreparations
duringtestingat differentstagesof this study.What is most
reassuringin thesedatais theconsistencyof CNPin augment-
ing basalcoronaryflowdespitesuchvariability.This finding
servesto reinforceour observationsabout CNP as a potent
exogenouscoronaryvasodilator.
Organchamberobservations.Of additionalsignificanceis
the findingthat CNP also mediatedpotent coronaryvasore-
laxingactionsin the organ chamber in isolatedepicardial
Table4. CardiacHemodynamicResponsesto L-NMMAInfusion
Baseline2: Baseline3:
Baseline1 CNP L-NMMA L-NMMA+ CNP L-Arginine Argirrine + CNP
CBF(ml/min) 93* 11 123~ 14” 91~ 11 132t 157 89~ 15 117L 16$
CD(~mol/liter) 43L 2.4 44~ 23 43~ 2.3 43f 2.2 42~ 2.9 42~ 27
CVR(mmHg/mlper rein) 1.46f 0.2 1.09t 0.1’ 1.54* 0.2 1.04t O.lt 1.61* 0.3 1.15i 0.2$
CO(liters/rein) 21 ~ (),2 2.0? 0.2 2.0? 0.2
CPP(mmHg) 128? 9 130t 9 123? 7
dP/dt(AmmHgk) 1,910t 188 2,068f 145* 1,752t 183* 1,890t 179 1,694* 162* 1,752? 231
SVR(mmHg/mlperrein) 65~ 8 70~ (J (j(jf 9
*p<0.05versusBaseline1.fp <0.05versusBaseline2.~p<0.05versusBaseline3.CD= coronarydiameter;CNP= C-typenatriureticpeptide;CVR= coronary
vascularesistance;L-NMMA= N’-monomethykarginine;otherabbreviationsas inTables2 and3.
JACC Vol. 28, No, 4
October 1996:1031-8








(l=X 10-7 ~olfliter) in the preseke and absenceof HS-142-1
(10-’ mofiliter).*p<O05 HS-142-lversuscorrtrofperiod WITH
EC =intact endothelium.
coronaryarteries. In the isolatedorgan chamberrings,we
demonstratedthat CNPmediatedpotentrelaxationofepicar-
dial coronaryarterieswhetheror not the endotheliumwas
intact.Indeed,in the initialset of experiments,the actionsof
CNPwereenhancedinde-endothelializedrings.Thisenhance-
mentwasnot observedin the secondseriesof controlringsin
theHS-142-1study,but the importantobservationisthatCNP
playsa directroleasa coronaryvasodilatorthat isindependent











surprisingbecauseCNP binds to a receptor that generates




tracellularcGMP,and both are potentvasodilators.The data
from the current investigationsupport their independent
mechanismsof action.Blockadeof the intracoronarynitric
oxidesynthasesystemdid alter the responseof cardiaccon-
tractilityto CNP. IntracoronaryL-NMMAreduced cardiac
contractility(dP/dt) and attenuated the abilityof CNP to




a directactionof intracoronaryCNPon ventricularmuscle,or
it may be indirectlyrelated to a generalizedincrease in
coronarybloodflow,aswiththe Greggphenomenon(21,22).
The increasein contractilitycouldalsobe secondaryto CNP
activationofan intermediatesubstancethataugmentscontrac-
tility.Recently,Pauliset al. (23)demonstratedthat the coro-
nary endotheliumalters cardiaccontractilityin a paracrine
manner,and Hare et al. (24)demonstratedthat nitricoxide
may contributeto the beta-adrenergichyporesponsiveness
observedin advancedheart failure. Our data suggestan





Figure 6. Four representativephotomicrographs
at x1OOmagnification.4 CNP stainingin the
smoothmuscleofan epicardialcoronaryartery.B,
CNP stainingin the endotheliumof a coronary
arteriole.C, IntenseCNPstainingin the smooth
muscleof a CNP-perfusedcoronaryartery. D,
Controlvesselstainedwithnormalrabbitserum.
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atescorona~relaxationin thepresenceandabsenceofanintact




endotheliumis not essentialfor the actionof CNP.Thisobser-
vationconfirmspreviousreports(3)ofenhancedCNPvasorelax-






The demonstrationthat CNPmediatesits actionsindepen-
dentof a functionalendotheliumisconsistentwithrecentwork
establishingendothelialcell synthesisand secretionof CNP
(9-11)andidentiljkrgthe receptorforCNPinvascularsmooth
muscle(8).Thecurrentobsewationsthereforesupporta hypoth-
esis that CNP is secretedby coronaryendotheliumand acts
througha paracrinemechanismonthecoronarysmoothmuscle,
muchlikeendothelinandnitricoxide(16,2.5).Ourobservations








in the coronarycirculationand supportsa role for CNP as a
paracinemediatorwithinthecoronmycirculation.
Summary.In summary,the current investigationdemon-
strates that CNP is a potent in vivoand in vitro coronary
vasodilator.It also demonstratesthat the in vitro actionsof
CNP are independentof a functionalendothelium.CNP
mediatesits coronaryvasodilationthroughactivationof par-
ticulateguanylatecyclaseand is independentof the coronary
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